Limitation of treatment at the end of life: an empirical-ethical analysis regarding the practices of physician members of the German Society for Palliative Medicine

作者:Schildmann Jan*; Hoetzel Julia; Baumann Anne; Mueller Busch Christof; Vollmann Jochen
来源:Journal of Medical Ethics, 2011, 37(6): 327-332.
DOI:10.1136/jme.2010.039248

摘要

Objectives To determine the frequencies and types of limitation of medical treatment performed by physician members of the German Society for Palliative Medicine and to analyse the findings with respect to clinical and ethical aspects of end-of-life practices.
Design Cross-sectional postal survey.
Setting Data collection via the secretary of the German Society for Palliative Medicine using the German language version of the EURELD survey instrument.
Subjects All 1645 physician members of the German Society for Palliative Medicine.
Main outcome measures Types and frequencies of limitation of treatment and possible determinants.
Results 901 physicians participated in the study (response rate 55.8%). Participants reported limitation of treatment in 69.1% of cases. These decisions most often affected artificial nutrition (19%), chemotherapy (14%), antibiotics (11%) and medication other than antibiotics (11%). In the majority of eligible cases, physicians estimated the life-shortening effect of limitation of treatment to be < 7 days. However, estimations differ depending on the medical measures in question. Bivariate statistical analysis indicated that withholding of treatment was performed significantly more frequently for patients aged >= 65 years (p = 0.019). In addition, there were significant associations between the incidence of limitation of treatment and the different diseases reported by respondents as the underlying cause of death.
Conclusion The findings of this study provide information on the current state of an ethically and clinically challenging aspect of clinical practice and can serve as a starting point for further interdisciplinary research on normative and empirical aspects of treatment decision-making at the end of life.